With the exception of genotoxic oncology drugs, first-in-human, Phase 1 clinical studies of investigational drugs have traditionally been conducted in healthy volunteers (HVs). The primary goal of these studies is to investigate the pharmacokinetics and pharmacodynamics of a novel drug candidate, determine appropriate dosing, and document safety and tolerability.
https://translational-medicine.biome...967-018-1710-5
The alternative would be giving an already sick person a substance never used
In humans before.
The possible risks would affect someone who is already sick much more.